Chardan Capital Maintains Buy on Prime Medicine, Lowers Price Target to $9
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $10 to $9.
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $10 to $9.